MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE

Lu Xin; Chen Zhiyuan; Mi Wenting; Zheng Jianming; Liu Yubin

doi:10.1515/med-2024-1060

Open Medicine (Nov 2024)

MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE

Lu Xin,
Chen Zhiyuan,
Mi Wenting,
Zheng Jianming,
Liu Yubin

Affiliations

Lu Xin: Department of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
Chen Zhiyuan: Department of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
Mi Wenting: Gastroenterology Department, Nanfang Hospital, Southern Medical University, Guangzhou, China
Zheng Jianming: Department of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
Liu Yubin: Department of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Second Road, Yuexiu District, Guangzhou, China

DOI: https://doi.org/10.1515/med-2024-1060
Journal volume & issue: Vol. 19, no. 1
pp. 2402 – 10

Abstract

Read online

This study aimed to investigate the role of microtubule-affinity regulatory protein kinase 1 (MARK1) in hepatocellular carcinoma (HCC) progression, its association with sorafenib sensitivity, and the interplay between MARK1 and POTE Ankyrin domain family member E(POTEE) in HCC cells.

Published in Open Medicine

ISSN: 2391-5463 (Online)
Publisher: De Gruyter
Country of publisher: Poland
LCC subjects: Medicine
Website: https://www.degruyter.com/journal/key/med/html

About the journal

Abstract

Keywords